Oligomers Are Promising Targets for Drug Development in the Treatment of Proteinopathies

Currently, there is no effective treatment of proteinopathies, as well as their diagnosis in the early stages of the disease until the first clinical symptoms appear. The proposed model of fibrillation of the Aβ peptide and its fragments not only describes molecular rearrangements, but also offers m...

Full description

Bibliographic Details
Main Author:	Oxana V. Galzitskaya
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-01-01
Series:	Frontiers in Molecular Neuroscience
Subjects:	amyloid oligomer drug polymorphism model
Online Access:	https://www.frontiersin.org/article/10.3389/fnmol.2019.00319/full

id	doaj-051a8288e4674d70a9666938bc8a5784
record_format	Article
spelling	doaj-051a8288e4674d70a9666938bc8a57842020-11-25T00:11:30ZengFrontiers Media S.A.Frontiers in Molecular Neuroscience1662-50992020-01-011210.3389/fnmol.2019.00319493527Oligomers Are Promising Targets for Drug Development in the Treatment of ProteinopathiesOxana V. Galzitskaya0Oxana V. Galzitskaya1Laboratory of Bioinformatics and Proteomics, Institute of Protein Research, Russian Academy of Sciences, Pushchino, RussiaLaboratory of the Structure and Function of Muscle Proteins, Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Pushchino, RussiaCurrently, there is no effective treatment of proteinopathies, as well as their diagnosis in the early stages of the disease until the first clinical symptoms appear. The proposed model of fibrillation of the Aβ peptide and its fragments not only describes molecular rearrangements, but also offers models of processes that occur during the formation of amyloid aggregates. Since this model is also characteristic of other proteins and peptides, a new potential target for drug development in the treatment of Alzheimer’s disease (AD) and other proteinopathies is proposed on the basis of this model. In our opinion, it is oligomers that are promising targets for innovative developments in the treatment of these diseases.https://www.frontiersin.org/article/10.3389/fnmol.2019.00319/fullamyloidoligomerdrugpolymorphismmodel
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Oxana V. Galzitskaya Oxana V. Galzitskaya
spellingShingle	Oxana V. Galzitskaya Oxana V. Galzitskaya Oligomers Are Promising Targets for Drug Development in the Treatment of Proteinopathies Frontiers in Molecular Neuroscience amyloid oligomer drug polymorphism model
author_facet	Oxana V. Galzitskaya Oxana V. Galzitskaya
author_sort	Oxana V. Galzitskaya
title	Oligomers Are Promising Targets for Drug Development in the Treatment of Proteinopathies
title_short	Oligomers Are Promising Targets for Drug Development in the Treatment of Proteinopathies
title_full	Oligomers Are Promising Targets for Drug Development in the Treatment of Proteinopathies
title_fullStr	Oligomers Are Promising Targets for Drug Development in the Treatment of Proteinopathies
title_full_unstemmed	Oligomers Are Promising Targets for Drug Development in the Treatment of Proteinopathies
title_sort	oligomers are promising targets for drug development in the treatment of proteinopathies
publisher	Frontiers Media S.A.
series	Frontiers in Molecular Neuroscience
issn	1662-5099
publishDate	2020-01-01
description	Currently, there is no effective treatment of proteinopathies, as well as their diagnosis in the early stages of the disease until the first clinical symptoms appear. The proposed model of fibrillation of the Aβ peptide and its fragments not only describes molecular rearrangements, but also offers models of processes that occur during the formation of amyloid aggregates. Since this model is also characteristic of other proteins and peptides, a new potential target for drug development in the treatment of Alzheimer’s disease (AD) and other proteinopathies is proposed on the basis of this model. In our opinion, it is oligomers that are promising targets for innovative developments in the treatment of these diseases.
topic	amyloid oligomer drug polymorphism model
url	https://www.frontiersin.org/article/10.3389/fnmol.2019.00319/full
work_keys_str_mv	AT oxanavgalzitskaya oligomersarepromisingtargetsfordrugdevelopmentinthetreatmentofproteinopathies AT oxanavgalzitskaya oligomersarepromisingtargetsfordrugdevelopmentinthetreatmentofproteinopathies
_version_	1725403597722615808

Oligomers Are Promising Targets for Drug Development in the Treatment of Proteinopathies

Similar Items